You searched for
Category:
Corporate
Chiesi Returns Seralutinib Rights to Gossamer Bio as Companies Terminate Collaboration and License Agreement
27/07/2026
Phase 3 PROSERA Topline Results for Seralutinib in Pulmonary Arterial Hypertension (PAH) Released Today
23/02/2026
In Memory of Dr. Paolo Chiesi: Visionary Leader and Innovator
05/03/2025
Code of Interdependence Workshop: a great opportunity for collaboration
25/09/2024
Chiesi to Present Data at the American Thoracic Society Conference
17/05/2024
Empowering Women in Science and Healthcare: Chiesi’s Commitment to Gender Equality
12/02/2024
Chiesi Partnership Day 2023
17/11/2023
Chiesi Open Day 2023: a day of sharing and discovery
24/10/2023
Chiesi Group and Statkraft sign a 10-year renewable energy PPA
19/10/2023
Inclusiveness, transparency and harmony: Chiesi Group introduces Human Rights Policy
31/07/2023
Chiesi’s 2022 Sustainability Report: “Purpose First”
27/07/2023
LEED certification: Chiesi's commitment for the sustainability of its buildings
31/05/2023
A behavioral therapy app to close the access gap in COPD treatment
18/04/2023
World Health Day: our commitment to provide Health For All
07/04/2023
European Parliament vote on the revision of the EU’s legislative framework on F-gas: climate targets need innovative solutions
03/04/2023